Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
The biology of roginolisib: Activity without immune toxicity
Industry Insight
End of year reflections from our CEO
Industry Insight
Driving breakthroughs for myelofibrosis care
Industry Insight
What’s next for cambritaxestat?
Industry Insight
Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas
Industry Insight
iOnctura expands roginolisib trials to the US
Industry Insight
iOnctura enhances board to accelerate growth and innovation
Industry Insight
Addressing drug resistance in non-small cell lung cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
Download our corporate deck
Find out more about our mission to give patients more momets that matter
All news
Data & publication
Safety and clinical efficacy of cambritaxestat (IOA-289), a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
Press release
iOnctura debuts cambritaxestat (IOA-289) clinical data in patients with pancreatic cancer at ESMO
Data & publication
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nabpaclitaxel (GnP) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
Data & publication
Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models
Data & publication
Autotaxin inhibition with IOA-289 decreases breast tumor growth in mice whereas knockout of autotaxin in adipocytes does not
Data & publication
IOA-289, an orally available type IV autotaxin inhibitor, ameliorates steatosis and fibrosis in a progressive preclinical murine NASH model
Data & publication
Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors
Press release
Peer-reviewed translational research paves the way for first-in-class autotaxin inhibitor IOA-289 in cancer
Press release
iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289
Data & publication
iOnctura data at AACR demonstrates unique mechanism of action for clinical stage autotaxin inhibitor IOA-289
Press release
iOnctura data at AACR demonstrates unique mechanism of action for clinical stage autotaxin inhibitor IOA-289
Press release
iOnctura to present preclinical data on its clinical stage autotaxin inhibitor, IOA-289, at AACR
Looking for media
resources?